Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
AL-Kindy College Medical Journal · 2024
DOI: 10.47723/2km3dk27 ↗Kurz gefasst
Fachartikel in der Zeitschrift AL-Kindy College Medical Journal, 2024. Verfasst von Yasameen Abbas und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods: A Cross sectional Observational study Started on 69 RA Records receiving Amgevita. Data collected from local registry then examined for disease activity and adverse reactions for 9 months follow up.
Results
Thirty patients completed the 9 months period of the study: aged (49±14) years; 77.5% females. After 3, 6 and 9 months of follow up, patients' mean (SD) CDAI 27.8 ( 13.60 ) which was statistically lower (19.80) (6.96), 17.70 (2.790), and 19 (1.040), p
Zitieren
APA
Abbas, Y., Ihsan, N., Adnan, A., Moayad, M., AlKazzaz, A., Maroof, A., Abdulrahman, A., Abdulateef, N., AlOsami, M., Gorial, F., Altahhan, M., Almansi, Z., & Alnoori, A. (2024). Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis. AL-Kindy College Medical Journal. https://doi.org/10.47723/2km3dk27
Vancouver
Abbas Y, Ihsan N, Adnan A, Moayad M, AlKazzaz A, Maroof A, et al. Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis. AL-Kindy College Medical Journal. 2024. doi:10.47723/2km3dk27
BibTeX
@article{Abbas2024,
author = {Abbas, Yasameen and Ihsan, Nabaa and Adnan, Asal and Moayad, Marwa and AlKazzaz, Ali and Maroof, Avin and Abdulrahman, Ali and Abdulateef, Nazar and AlOsami, Mohammad and Gorial, Faiq and Altahhan, Mohammed and Almansi, Zahraa and Alnoori, Ali},
title = {Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis},
journal = {AL-Kindy College Medical Journal},
year = {2024},
doi = {10.47723/2km3dk27}
}
EUVIMED